Abstract: SA-PO0676
Real-World Kidney Outcomes Among C5 Inhibitor-Naive Patients Treated with First-Line Ravulizumab Therapy for Atypical Hemolytic Uremic Syndrome (aHUS)
Session Information
- Glomerular Diseases: Clinical, Outcomes, and Therapeutics Research - Other
October 24, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Memon, Aliza Anwar, SLUCare Physician Group, St. Louis, Missouri, United States
- Yumagulov, Marat, Alexion Pharmaceuticals Inc, Boston, Massachusetts, United States
- Armstrong, David S., Alexion Pharmaceuticals Inc, Boston, Massachusetts, United States
- Singhal, Ruchi, Optum Inc, Eden Prairie, Minnesota, United States
- Steiger, Christina, Optum Inc, Eden Prairie, Minnesota, United States
- Amos, Qiana, Optum Inc, Eden Prairie, Minnesota, United States
- Burton, Tanya, Alexion Pharmaceuticals Inc, Boston, Massachusetts, United States
Background
Complement C5 inhibitors (C5i) are standard of care for aHUS. We assessed clinical features and kidney outcomes in C5i-naive aHUS patients starting ravulizumab (RAVU) in routine practice to better characterize this group.
Methods
A retrospective observational study using Komodo’s Healthcare Map identified patients with ≥2 medical claims for an aHUS specific or related diagnosis code ≥30 days apart and ≥1 claim for RAVU between 01Jan2019 and 31Mar2025. The index date was the first RAVU claim. We excluded patients with a claim at any time for thrombotic thrombocytopenic purpura (TTP), Shiga toxin–producing E. coli (STEC) infection, hematopoietic stem cell transplantation–associated thrombotic microangiopathy (HSCT-TMA), or other approved C5i indications. We also excluded patients with any C5i use or an aHUS-related hospitalization, which may have included C5i use, during the 6 months pre-index period. Supportive care, renal outcomes, and healthcare resource utilization were compared during the 6 month pre-and post-index periods using paired t-tests and McNemar’s tests.
Results
Among 182 patients, mean (SD) age was 38 (21) years; 42% were male; insurance coverage was commercial 43%, Medicare 25%, and Medicaid 27%. Pre-index clinical features included hemolytic anemia (71%), viral or bacterial infection (67%), thrombocytopenia (30%), autoimmune disease (12%), prior renal transplantation (7%), hypertensive emergency (10%), malignancy (8%), and pregnancy (5%). Comparing 6 months pre- vs post-index, fewer patients received blood transfusions (24% vs 12%, p<0.001) and plasma infusion/exchange (9% vs 1%, p<0.001). Prior to RAVU initiation, 52 (29%) patients received dialysis. Of these, 18 (35%) discontinued dialysis within 6 months post-index. All-cause inpatient hospitalizations (31% vs 18%, p=0.002) decreased from 6 months pre- to post-index.
Conclusion
In C5i-naive patients with aHUS, RAVU initiation was associated with reduced supportive care needs (blood transfusions, plasma infusion/exchange), dialysis discontinuation, and fewer hospitalizations—suggesting improved disease control and a potential shift toward lower cost of care settings.